The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two ...

Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but ...

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped ...

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers ...

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.

The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S.

In an interview with Stephen Onikoro, chief operating officer of PharmaForceIQ, he shared that pharma marketers can’t pour ...

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...